References

Atun, R. and I. Olynik, 2008. Resistance to implementing policy change: The case of Ukraine. Bull. World Health Org., 86: 147-154.

Chan, E.D., V. Laurel, M.J. Strand, J.F. Chan, M.L. Huynh, M. Goble and M.D Iseman, 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med., 169: 1103-1109.

Chechitiany, R., V. Pylypchuk, O. Argzanova, N. Prihoda, L. Vichrova, E. Zagaydanova and G. Kutsyna, 2007. Comparative effect of an immunomodulator immunoxel (Dzherelo) when used alone or in combination with antiretroviral therapy in drug-na�ve HIV infected individuals. Int. J. Biotechnol., 9: 267-276.
Direct Link  |  

Condos, R., W.N. Rom and N.W. Schluger, 1997. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet, 349: 1513-1515.

Drobniewski, F., V. Nikolayevsky, A. Asmolov, Y. Bazhora and S. Servetsky, 2005. Increasing trends in HIV and TB rates in Odessa and the Ukraine. Intl. J. STD AIDS, 16: 374-378.

Dubrovina, I., K. Miskinis, S. Lyepshina, Y. Yann and H. Hoffmann et al., 2008. Drug resistant tuberculosis and HIV in Ukraine: A threatening convergence of two epidemics? Int. J. Tuberculosis Lung Dis., 12: 756-762.

Dye, C., C.J. Watt, D.M. Bleed, S.M. Hosseini and M.C. Raviglione, 2005. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence and deaths globally. J. Am. Med. Assoc., 293: 2767-2775.
PubMed  |  

Espinal, M.A., S.J. Kim, P.G. Suarez, K.M. Kam and A.G. Khomenko et al., 2000. Standard short course chemotherapy for drug resistant tuberculosis: Treatment outcomes in 6 countries. J. Am. Med. Assoc., 283: 2537-2545.

Fu, Y., N.H. Chu, S.L. Yuan, W. Chen and W. Wang et al., 2008. The effect of interventional therapy in multimodality treatment on multi drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi, 31: 95-98.

Grahmann, P.R. and P.K. Braun, 2008. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: A case study. Int J. Tuberculosis Lung Dis., 12: 636-644.

Greinert, U., D. Hillemann, C. Lange and E. Richter, 2007. Antibiotic drug resistant tuberculosis. Med. Klin. (Munich), 102: 957-966.
Direct Link  |  

Kaufmann, S.H., 2006. Tuberculosis: Back on the immunologists' agenda. Immunity, 24: 351-357.

Kolodziej, H., 2008. Aqueous ethanolic extract of the roots of pelargonium sidoides-new scientific evidence for an old anti-infective phytopharmaceutical. Planta Med., 74: 661-666.

Melnik, V.P., O.V. Panasyuk, V.S. Pylypchuk, O.P. Moshich, N.M. Procenko and O.M. Leonenko, 1999. Deployment of herbal preparations Dzherelo and Svitanok for combination therapy of pulmonary tuberculosis. Medical Institute of Ukrainian Association of People�s Medicine. Information Bulletin of the Ministry of Health of Autonomous Republic of Crimea. UDK:616.24-002.5-085-038:615.017. 1999. Kiev, Ukraine.

Newton, S.M., C. Lau and C.W. Wright, 2000. A review of antimycobacterial natural products. Phytother. Res., 14: 303-322.
CrossRef  |  PubMed  |  

Nikolaeva, L.G., T.V. Maystat, V.S. Pylypchuk, Y.L. Volyanskii, L.A. Masyuk and G.A. Kutsyna, 2008. Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug Design Dev. Ther., 2: 87-93.
CrossRef  |  PubMed  |  Direct Link  |  

Nikolaeva, L.G., T.V. Maystat, V.S. Pylypchuk, Y.L. Volyanskii, L.A. Masyuk and G.A. Kutsyna, 2008. Effect of oral immunomodulator Dzherelo (Immunoxel) in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS. Intl. Immunopharmacol., 8: 845-851.
CrossRef  |  

Nikolayevskyy, V.V., T.J. Brown, Y.I. Bazhora, A.A. Asmolov, Y.M. Balabanova and F.A. Drobniewski, 2007. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the Southern Ukraine. Clin. Microbiol. Infect., 13: 129-138.

Prihoda, N.D., O.V. Arjanova, L.V. Yurchenko, N.I. Sokolenko, L.A. Vihrova, V.S. Pylypchuk and G.A. Kutsyna, 2007. Open label trial of adjuvant immunotherapy with Dzherelo, Svitanok and Lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOT. J. Med. Plant Res., 1: 117-122.
Direct Link  |  

Prihoda, N.D., O.V. Arjanova, L.V. Yurchenko, N.I. Sokolenko, L.A. Vihrova, V.S. Pylypchuk and G.A. Kutsyna, 2008. Adjunct immunotherapy of tuberculosis in drug-resistant TB and TB/HIV co-infected patients. Int. J. Biomed. Pharm. Sci., 2: 59-64.
Direct Link  |  

Pylypchuk, V.S., 2003. Clinical and experimental aspects rationalizing the need for immunotherapy in the treatment of patients with tuberculosis. Probl. Ecol. Med. Gen. Clin. Immunol., 70: 75-84.

Shin, S.S., A.D. Pasechnikov, I.Y. Gelmanova, G.G. Peremitin and A.K. Strelis et al., 2007. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int. J. Tuberculosis Lung Dis., 11: 1314-1320.

Stanford, J.L., C.A. Stanford, J.M. Grange, N.N. Lan and A. Etemadi, 2001. Does immunotherapy with heat killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis? Respir. Med., 95: 444-447.

Tomioka, H., 2004. Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Design, 10: 3297-3312.

Wallis, R.S., 2005. Reconsidering adjuvant immunotherapy for tuberculosis. Clin. Infect. Dis., 41: 201-208.

Zaitzeva, S.I., S.L. Matveeva, T.G. Gerasimova, Y.N. Pashkov, D.A. Butov, V.S. Pylypchuk and G.A. Kutsyna, 2008. Treatment of cavitary and infiltrating pulmonary TB with or without immunomodulator Dzherelo. Clin. Microbiol. Infect.

Zheng, X.M., S.M. Li and B.C. Xing, 2004. Short term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. vaccae on multi-drug resistant pulmonary tuberculosis. Di Yi Jun Yi Da Xue Xue Bao, 24: 574-578.